Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Equity Average (2019 - 2026)

C4 Therapeutics has reported Equity Average over the past 8 years, most recently at $245.4 million for Q1 2026.

  • For Q1 2026, Equity Average rose 19.39% year-over-year to $245.4 million; the TTM value through Mar 2026 reached $245.4 million, up 19.39%, while the annual FY2025 figure was $236.3 million, 2.27% up from the prior year.
  • Equity Average for Q1 2026 was $245.4 million at C4 Therapeutics, up from $205.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $377.1 million in Q1 2022 and troughed at $164.2 million in Q3 2025.
  • A 5-year average of $254.8 million and a median of $245.4 million in 2026 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: skyrocketed 38.5% in 2022 and later tumbled 32.93% in 2025.
  • Year by year, Equity Average stood at $303.7 million in 2022, then dropped by 23.92% to $231.1 million in 2023, then decreased by 0.76% to $229.3 million in 2024, then dropped by 10.39% to $205.5 million in 2025, then increased by 19.43% to $245.4 million in 2026.
  • Business Quant data shows Equity Average for CCCC at $245.4 million in Q1 2026, $205.5 million in Q4 2025, and $164.2 million in Q3 2025.